» Articles » PMID: 33805598

Targeting Intercellular Communication in the Bone Microenvironment to Prevent Disseminated Tumor Cell Escape from Dormancy and Bone Metastatic Tumor Growth

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Apr 3
PMID 33805598
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Metastasis to the bone is a common feature of many cancers including those of the breast, prostate, lung, thyroid and kidney. Once tumors metastasize to the bone, they are essentially incurable. Bone metastasis is a complex process involving not only intravasation of tumor cells from the primary tumor into circulation, but extravasation from circulation into the bone where they meet an environment that is generally suppressive of their growth. The bone microenvironment can inhibit the growth of disseminated tumor cells (DTC) by inducing dormancy of the DTC directly and later on following formation of a micrometastatic tumour mass by inhibiting metastatic processes including angiogenesis, bone remodeling and immunosuppressive cell functions. In this review we will highlight some of the mechanisms mediating DTC dormancy and the complex relationships which occur between tumor cells and bone resident cells in the bone metastatic microenvironment. These inter-cellular interactions may be important targets to consider for development of novel effective therapies for the prevention or treatment of bone metastases.

Citing Articles

Novel Approaches to Monitor Pharmacokinetics and Metabolism of Gemcitabine-Ibandronate Conjugate in Mice and Dogs.

Klawitter J, Easton M, Karpeisky A, Farrell K, Thamm D, Shokati T Molecules. 2025; 30(2).

PMID: 39860223 PMC: 11767451. DOI: 10.3390/molecules30020354.


New insights into non-small cell lung cancer bone metastasis: mechanisms and therapies.

Xue M, Ma L, Zhang P, Yang H, Wang Z Int J Biol Sci. 2024; 20(14):5747-5763.

PMID: 39494330 PMC: 11528464. DOI: 10.7150/ijbs.100960.


Review on effects and mechanisms of plant-derived natural products against breast cancer bone metastasis.

Zhang X, Miao J, Song Y, Zhang J, Miao M Heliyon. 2024; 10(18):e37894.

PMID: 39318810 PMC: 11420494. DOI: 10.1016/j.heliyon.2024.e37894.


Upregulation of CKS2 in immunosuppressive cells is associated with metastasis and poor prognosis in prostate cancer: a single-cell RNA-sequencing analysis.

Liang X, Huang R, Ping X, Deng W, Xiang S, Wang Z Transl Cancer Res. 2024; 13(8):3996-4009.

PMID: 39262475 PMC: 11385535. DOI: 10.21037/tcr-23-2100.


Bone targeted nano-drug and nano-delivery.

Wu Y, Sun B, Tang Y, Shen A, Lin Y, Zhao X Bone Res. 2024; 12(1):51.

PMID: 39231955 PMC: 11375042. DOI: 10.1038/s41413-024-00356-2.


References
1.
Jee S, Chu C, Chiu H, Huang Y, Tsai W, Liao Y . Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Invest Dermatol. 2004; 123(6):1169-75. DOI: 10.1111/j.0022-202X.2004.23497.x. View

2.
Aggarwal B, Sethi G, Ahn K, Sandur S, Pandey M, Kunnumakkara A . Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci. 2007; 1091:151-69. DOI: 10.1196/annals.1378.063. View

3.
Wu A, He Y, Broomfield A, Paatan N, Harrington B, Tseng H . CD169(+) macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer. J Pathol. 2016; 239(2):218-30. DOI: 10.1002/path.4718. View

4.
Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A . Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene. 2002; 21(46):7001-10. DOI: 10.1038/sj.onc.1205859. View

5.
Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J . AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015; 7(314):314ra185. PMC: 5279222. DOI: 10.1126/scitranslmed.aac5272. View